Arcutis Biotherapeutics (NASDAQ:ARQT) just reported results for the second quarter of 2024.
- Arcutis Biotherapeutics reported earnings per share of -42 cents. This was above the analyst estimate for EPS of -57 cents.
- The company reported revenue of $30.86 million.
- This was 13.78% better than the analyst estimate for revenue of $27.12 million.